Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-03-31 | 2005-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 31,102,000 | 34,086,000 | 39,183,000 | 41,362,000 | 116,959,000 | 112,911,000 | 132,290,000 | 152,825,000 | 147,685,000 | 160,738,000 | 32,605,000 | 31,594,000 | 37,914,000 | 48,572,000 | 24,229,000 | 28,567,000 | 19,188,000 | 20,419,000 | 17,937,000 | 32,918,000 | 30,129,000 | 43,555,000 | 89,551,000 | 23,548,000 | 27,856,000 | 34,859,000 | 20,238,000 | 23,368,000 | 32,241,000 | 27,148,000 | 19,813,000 | 21,933,000 | 17,418,000 | 20,242,000 | 25,154,000 | 20,047,000 | 15,024,000 | 20,453,000 | 19,206,000 | 12,972,000 | 14,557,000 | 14,271,000 | 15,824,000 | 12,934,000 | 16,761,000 | 12,898,000 | 12,123,000 | 10,287,000 | 10,284,000 | 11,671,000 | 9,983,000 | 9,179,000 | 6,429,000 | 9,326,000 | 10,439,000 | 11,081,000 | 10,113,000 | 9,153,000 | 8,073,000 | 9,197,000 | 7,976,000 | 9,566,000 | 11,968,000 | 13,093,000 | 10,952,000 | 15,861,000 | 15,002,000 | |||||||||
patient accounts receivable, less benefit from credit losses of 4,263 and 3,506, respectively | 67,629,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other | 23,672,000 | 27,429,000 | 26,136,000 | 26,626,000 | 20,056,000 | 21,669,000 | 21,774,000 | 17,854,000 | 18,469,000 | 16,852,000 | 17,816,000 | 16,671,000 | 19,146,000 | 18,915,000 | 18,239,000 | 16,144,000 | 10,093,000 | 9,025,000 | 8,621,000 | 9,039,000 | 9,878,000 | 9,983,000 | 11,650,000 | 9,823,000 | 10,462,000 | 10,724,000 | 7,237,000 | 6,742,000 | 9,609,000 | 8,589,000 | 6,504,000 | 5,655,000 | 6,992,000 | 5,662,000 | 6,346,000 | |||||||||||||||||||||||||||||||||||||||||
other current assets | 16,032,000 | 13,061,000 | 15,274,000 | 10,555,000 | 10,833,000 | 12,438,000 | 11,715,000 | 10,830,000 | 9,387,000 | 9,924,000 | 10,726,000 | 11,067,000 | 6,085,000 | 3,810,000 | 4,040,000 | 4,183,000 | 3,687,000 | 5,111,000 | 3,846,000 | 3,773,000 | 3,198,000 | 2,572,000 | 4,822,000 | 5,787,000 | 7,098,000 | 7,102,000 | 5,238,000 | 4,353,000 | 4,908,000 | 5,247,000 | 3,050,000 | 4,786,000 | 5,444,000 | 6,932,000 | 3,827,000 | 4,428,000 | 10,800,000 | 8,220,000 | 8,298,000 | 6,509,000 | 5,291,000 | 6,186,000 | 5,076,000 | 2,703,000 | 3,040,000 | 4,098,000 | 4,482,000 | 1,878,000 | 3,862,000 | 5,975,000 | 4,956,000 | 5,328,000 | 5,248,000 | 5,737,000 | 6,232,000 | 5,179,000 | 3,466,000 | 3,736,000 | 2,944,000 | 3,356,000 | 2,124,000 | 2,959,000 | 2,260,000 | 2,103,000 | 2,334,000 | 1,857,000 | 1,752,000 | 2,098,000 | 1,509,000 | 1,333,000 | 2,173,000 | 2,031,000 | 2,067,000 | 2,251,000 | 1,692,000 | 1,428,000 |
total current assets | 138,435,000 | 140,532,000 | 145,353,000 | 137,583,000 | 204,870,000 | 201,677,000 | 221,142,000 | 233,375,000 | 228,499,000 | 241,799,000 | 117,794,000 | 111,266,000 | 112,892,000 | 121,846,000 | 95,843,000 | 95,166,000 | 79,424,000 | 79,699,000 | 75,798,000 | 87,636,000 | 82,644,000 | 92,139,000 | 148,672,000 | 85,386,000 | 92,534,000 | 107,009,000 | 81,156,000 | 79,214,000 | 90,657,000 | 86,408,000 | 75,595,000 | 77,081,000 | 73,415,000 | 79,606,000 | 78,571,000 | 65,964,000 | 66,618,000 | 70,364,000 | 68,066,000 | 55,649,000 | 55,899,000 | 54,851,000 | 56,615,000 | 51,847,000 | 54,254,000 | 49,660,000 | 45,157,000 | 41,429,000 | 44,722,000 | 45,322,000 | 44,063,000 | 44,644,000 | 47,123,000 | 45,667,000 | 45,836,000 | 44,252,000 | 44,060,000 | 39,284,000 | 38,064,000 | 35,212,000 | 39,223,000 | 33,019,000 | 36,007,000 | 36,945,000 | 39,766,000 | 38,721,000 | 38,712,000 | 39,525,000 | 39,307,000 | 36,033,000 | 38,790,000 | 39,020,000 | 39,095,000 | 35,981,000 | 38,764,000 | 36,852,000 |
fixed assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
furniture and equipment | 67,522,000 | 66,756,000 | 68,802,000 | 68,128,000 | 66,782,000 | 65,775,000 | 65,550,000 | 63,982,000 | 64,507,000 | 63,429,000 | 63,139,000 | 62,074,000 | 62,006,000 | 60,379,000 | 60,205,000 | 58,743,000 | 58,179,000 | 57,538,000 | 56,754,000 | 55,426,000 | 55,411,000 | 55,914,000 | 56,873,000 | 54,942,000 | 54,464,000 | 52,831,000 | 53,267,000 | 52,611,000 | 52,473,000 | 51,923,000 | 51,569,000 | 51,100,000 | 51,822,000 | 50,644,000 | 49,820,000 | 48,426,000 | 46,996,000 | 46,747,000 | 45,654,000 | 43,495,000 | 42,542,000 | 42,003,000 | 42,104,000 | 41,310,000 | 39,472,000 | 38,965,000 | 37,496,000 | 37,941,000 | 36,960,000 | 36,316,000 | 35,853,000 | 35,230,000 | 35,491,000 | 35,103,000 | 35,024,000 | 33,953,000 | 33,943,000 | 33,563,000 | 32,491,000 | 32,220,000 | 32,154,000 | 31,973,000 | 32,207,000 | 32,121,000 | 32,150,000 | 30,947,000 | 30,421,000 | 29,929,000 | 29,281,000 | 28,782,000 | 28,124,000 | 24,650,000 | 24,098,000 | 23,718,000 | 23,884,000 | 23,010,000 |
leasehold improvements | 58,015,000 | 55,218,000 | 53,504,000 | 51,105,000 | 48,385,000 | 48,730,000 | 47,458,000 | 46,941,000 | 46,212,000 | 45,096,000 | 43,525,000 | 42,877,000 | 41,961,000 | 41,038,000 | 40,541,000 | 39,194,000 | 37,413,000 | 35,986,000 | 35,492,000 | 35,320,000 | 34,111,000 | 33,631,000 | 32,873,000 | 33,247,000 | 31,948,000 | 31,020,000 | 33,089,000 | 31,712,000 | 31,101,000 | 30,421,000 | 29,981,000 | 29,760,000 | 28,449,000 | 27,729,000 | 27,582,000 | 26,765,000 | 26,206,000 | 25,733,000 | 25,547,000 | 24,107,000 | 23,565,000 | 22,806,000 | 22,639,000 | 22,065,000 | 21,701,000 | 21,891,000 | 22,170,000 | 21,404,000 | 21,353,000 | 20,858,000 | 20,598,000 | 20,407,000 | 19,987,000 | 20,385,000 | 19,990,000 | 19,733,000 | 19,587,000 | 19,590,000 | 19,240,000 | 18,999,000 | 18,916,000 | 19,012,000 | 19,209,000 | 18,581,000 | 18,175,000 | 18,061,000 | 17,792,000 | 17,512,000 | 17,068,000 | 17,352,000 | 17,325,000 | 16,171,000 | 15,554,000 | 15,226,000 | 14,835,000 | 14,556,000 |
fixed assets, gross | 125,537,000 | 121,974,000 | 122,306,000 | 119,233,000 | 115,167,000 | 114,505,000 | 113,008,000 | 110,923,000 | 110,719,000 | 108,525,000 | 106,664,000 | 104,951,000 | 103,967,000 | 101,417,000 | 100,746,000 | 97,937,000 | 95,592,000 | 93,524,000 | 92,246,000 | 90,746,000 | 89,522,000 | 89,545,000 | 89,746,000 | 88,189,000 | 86,412,000 | 83,851,000 | 86,356,000 | 84,323,000 | 83,574,000 | 82,344,000 | 81,550,000 | 80,860,000 | 80,271,000 | 78,373,000 | 77,402,000 | 75,191,000 | 73,202,000 | 72,480,000 | 71,201,000 | 64,809,000 | ||||||||||||||||||||||||||||||||||||
less accumulated depreciation and amortization | -91,315,000 | -89,853,000 | -89,542,000 | -87,093,000 | -88,602,000 | -88,277,000 | -86,757,000 | -84,821,000 | 84,651,000 | 83,548,000 | 82,026,000 | 80,203,000 | 78,960,000 | 77,188,000 | 76,601,000 | 74,958,000 | 73,556,000 | 71,964,000 | 70,485,000 | 69,081,000 | 68,048,000 | 67,011,000 | 66,764,000 | 66,099,000 | 65,040,000 | 63,829,000 | 65,197,000 | 64,154,000 | 63,608,000 | 62,652,000 | 61,742,000 | 60,475,000 | 59,517,000 | 58,200,000 | 57,235,000 | 56,018,000 | 55,760,000 | 55,642,000 | 54,512,000 | 51,098,000 | 50,212,000 | 49,045,000 | 48,685,000 | 47,517,000 | 46,543,000 | 45,896,000 | 46,150,000 | 45,588,000 | 44,922,000 | 44,158,000 | 43,634,000 | 42,747,000 | 42,556,000 | 42,299,000 | 41,432,000 | 40,940,000 | 39,998,000 | 39,230,000 | 38,546,000 | 37,816,000 | 37,185,000 | 36,646,000 | 36,314,000 | 35,131,000 | 34,105,000 | 33,167,000 | 32,106,000 | 30,893,000 | 30,086,000 | 29,342,000 | 28,373,000 | 27,628,000 | 26,618,000 | 25,573,000 | 24,591,000 | 23,825,000 |
fixed assets | 34,222,000 | 32,121,000 | 32,764,000 | 32,140,000 | 26,565,000 | 26,228,000 | 26,251,000 | 26,102,000 | 26,068,000 | 24,977,000 | 24,638,000 | 24,748,000 | 25,007,000 | 24,229,000 | 24,145,000 | 22,979,000 | 22,036,000 | 21,560,000 | 21,761,000 | 21,665,000 | 21,474,000 | 22,534,000 | 22,982,000 | 22,090,000 | 21,372,000 | 20,022,000 | 21,159,000 | 20,169,000 | 19,966,000 | 19,692,000 | 19,808,000 | 20,385,000 | 20,754,000 | 20,173,000 | 20,167,000 | 19,173,000 | 17,442,000 | 16,838,000 | 16,689,000 | 15,764,000 | ||||||||||||||||||||||||||||||||||||
operating lease right-of-use assets | 139,926,000 | 137,248,000 | 133,197,000 | 133,936,000 | 103,938,000 | 105,484,000 | 102,113,000 | 103,431,000 | 102,665,000 | 101,582,000 | 100,604,000 | 103,004,000 | 100,967,000 | 101,274,000 | 94,243,000 | 96,427,000 | 92,952,000 | 87,090,000 | 81,553,000 | 81,595,000 | 78,784,000 | 82,965,000 | 83,619,000 | 81,586,000 | 79,793,000 | 74,930,000 | 77,870,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
investment in unconsolidated affiliate | 12,289,000 | 12,320,000 | 12,273,000 | 12,190,000 | 12,168,000 | 12,243,000 | 12,160,000 | 12,256,000 | 12,256,000 | 12,229,000 | 12,160,000 | 12,131,000 | 11,978,000 | 12,346,000 | 12,422,000 | 12,215,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill | 690,412,000 | 677,595,000 | 674,387,000 | 667,152,000 | 554,642,000 | 548,970,000 | 534,271,000 | 509,571,000 | 522,907,000 | 506,703,000 | 501,347,000 | 494,101,000 | 449,548,000 | 442,761,000 | 443,692,000 | 434,679,000 | 374,047,000 | 373,887,000 | 360,176,000 | 345,646,000 | 336,946,000 | 330,894,000 | 330,769,000 | 317,676,000 | 316,639,000 | 303,549,000 | 293,338,000 | 293,525,000 | 293,630,000 | 284,624,000 | 273,770,000 | 271,338,000 | 268,050,000 | 267,957,000 | 244,446,000 | 226,806,000 | 191,231,000 | 191,268,000 | 191,051,000 | 170,914,000 | 159,176,000 | 147,914,000 | 150,471,000 | 156,207,000 | 142,517,000 | 143,955,000 | 105,234,000 | 112,248,000 | 103,581,000 | 100,188,000 | 99,716,000 | 99,141,000 | 93,797,000 | 92,750,000 | 91,452,000 | 76,588,000 | 79,410,000 | 79,424,000 | 67,327,000 | 67,359,000 | 68,801,000 | 57,247,000 | 56,069,000 | 56,097,000 | 55,886,000 | 55,886,000 | 48,932,000 | 49,788,000 | 40,631,000 | 37,650,000 | 39,759,000 | 21,082,000 | 21,082,000 | 20,997,000 | 15,193,000 | 14,339,000 |
other identifiable intangible assets | 176,429,000 | 175,627,000 | 177,328,000 | 179,311,000 | 124,309,000 | 123,903,000 | 116,888,000 | 109,682,000 | 112,112,000 | 107,592,000 | 108,991,000 | 108,755,000 | 93,697,000 | 92,655,000 | 91,546,000 | 86,382,000 | 60,086,000 | 59,216,000 | 57,593,000 | 56,280,000 | 54,060,000 | 54,895,000 | 55,648,000 | 52,588,000 | 53,385,000 | 50,055,000 | 48,125,000 | 48,828,000 | 49,311,000 | 48,435,000 | 47,092,000 | 48,954,000 | 47,568,000 | 48,321,000 | 43,213,000 | 38,060,000 | 33,389,000 | 33,909,000 | 34,428,000 | |||||||||||||||||||||||||||||||||||||
other assets | 4,557,000 | 4,157,000 | 4,385,000 | 5,155,000 | 2,699,000 | 4,629,000 | 4,431,000 | 2,821,000 | 5,679,000 | 4,699,000 | 2,593,000 | 4,149,000 | 5,619,000 | 1,333,000 | 1,972,000 | 1,578,000 | 1,553,000 | 1,506,000 | 1,509,000 | 1,539,000 | 1,530,000 | 1,591,000 | 1,563,000 | 1,519,000 | 1,470,000 | 1,445,000 | 1,439,000 | 1,430,000 | 1,405,000 | 1,384,000 | 1,357,000 | 1,224,000 | 1,200,000 | 1,268,000 | 1,274,000 | 1,228,000 | 1,221,000 | 1,219,000 | 1,200,000 | 1,086,000 | 1,916,000 | 1,115,000 | 1,978,000 | 1,141,000 | 1,317,000 | 1,081,000 | 1,078,000 | 967,000 | 953,000 | 1,042,000 | 1,018,000 | 1,435,000 | 1,079,000 | 2,043,000 | 3,396,000 | 3,303,000 | 2,206,000 | 922,000 | 930,000 | 923,000 | 885,000 | 869,000 | 855,000 | 849,000 | 834,000 | 1,347,000 | 1,770,000 | 2,094,000 | 1,476,000 | 1,847,000 | 2,777,000 | 1,585,000 | 1,591,000 | 1,108,000 | 950,000 | 1,587,000 |
total assets | 1,196,270,000 | 1,179,600,000 | 1,179,687,000 | 1,167,467,000 | 1,029,191,000 | 1,023,134,000 | 1,017,256,000 | 997,238,000 | 1,010,186,000 | 999,581,000 | 868,127,000 | 858,154,000 | 799,708,000 | 796,444,000 | 763,863,000 | 749,426,000 | 630,098,000 | 622,958,000 | 598,390,000 | 594,361,000 | 575,438,000 | 585,018,000 | 643,253,000 | 560,845,000 | 565,193,000 | 557,010,000 | 523,087,000 | 443,166,000 | 454,969,000 | 440,543,000 | 417,622,000 | 418,982,000 | 410,987,000 | 417,325,000 | 387,671,000 | 351,231,000 | 309,901,000 | 313,598,000 | 311,434,000 | 244,551,000 | ||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interest, usph shareholders’ equity and non-controlling interest | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable - trade | 7,417,000 | 4,200,000 | 6,088,000 | 5,936,000 | 6,361,000 | 4,100,000 | 4,866,000 | 3,898,000 | 4,509,000 | 3,674,000 | 4,233,000 | 3,300,000 | 4,471,000 | 3,793,000 | 3,272,000 | 3,268,000 | 1,532,000 | 1,782,000 | 1,955,000 | 1,335,000 | 1,060,000 | 1,802,000 | 2,950,000 | 2,494,000 | 2,863,000 | 2,426,000 | 1,894,000 | 2,019,000 | 2,067,000 | 1,705,000 | 1,722,000 | 2,165,000 | 1,754,000 | 1,613,000 | 1,996,000 | 1,634,000 | 2,181,000 | 1,668,000 | 2,244,000 | 1,451,000 | 2,292,000 | 1,782,000 | 1,901,000 | 1,835,000 | 1,423,000 | 1,722,000 | 1,275,000 | 1,585,000 | 1,399,000 | |||||||||||||||||||||||||||
accrued expenses | 56,901,000 | 65,436,000 | 68,326,000 | 59,513,000 | 64,506,000 | 58,056,000 | 53,749,000 | 55,344,000 | 35,846,000 | 43,338,000 | 45,220,000 | 37,413,000 | 33,784,000 | 41,246,000 | 51,121,000 | 45,705,000 | 50,267,000 | 44,720,000 | 51,671,000 | 59,746,000 | 60,236,000 | 51,325,000 | 40,645,000 | 30,855,000 | 33,573,000 | 31,346,000 | 39,237,000 | 38,493,000 | 40,128,000 | 35,367,000 | 38,342,000 | 33,342,000 | 31,492,000 | 31,235,000 | 30,820,000 | 21,756,000 | 23,216,000 | 26,273,000 | 20,684,000 | 19,446,000 | 18,178,000 | 22,839,000 | 19,081,000 | 20,112,000 | 17,147,000 | 20,625,000 | 14,779,000 | 15,298,000 | 11,661,000 | 14,116,000 | 12,672,000 | 14,200,000 | 10,656,000 | 14,082,000 | 11,349,000 | 12,734,000 | 25,283,000 | 12,744,000 | 13,450,000 | 10,429,000 | 12,559,000 | 12,459,000 | 13,479,000 | 10,810,000 | 11,552,000 | 11,752,000 | 12,179,000 | 9,328,000 | 9,065,000 | 9,071,000 | 9,535,000 | 6,440,000 | 9,031,000 | 7,007,000 | 6,774,000 | 5,150,000 |
current portion of operating lease liabilities | 41,960,000 | 41,038,000 | 40,124,000 | 39,835,000 | 34,828,000 | 35,243,000 | 34,699,000 | 35,252,000 | 34,446,000 | 31,274,000 | 33,650,000 | 33,709,000 | 32,540,000 | 32,083,000 | 30,625,000 | 30,475,000 | 29,197,000 | 27,860,000 | 27,292,000 | 27,512,000 | 26,905,000 | 29,591,000 | 26,826,000 | 26,486,000 | 25,644,000 | 22,558,000 | 26,733,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
current portion of term loan and notes payable | 8,802,000 | 8,168,000 | 9,257,000 | 10,999,000 | 9,605,000 | 9,700,000 | 9,222,000 | 7,691,000 | 7,555,000 | 7,530,000 | 7,730,000 | 7,863,000 | 7,490,000 | 4,780,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total current liabilities | 115,080,000 | 118,842,000 | 123,795,000 | 116,283,000 | 115,300,000 | 107,099,000 | 102,536,000 | 102,185,000 | 82,356,000 | 85,816,000 | 90,833,000 | 85,489,000 | 81,488,000 | 85,105,000 | 89,020,000 | 83,481,000 | 81,668,000 | 75,379,000 | 90,825,000 | 93,492,000 | 93,200,000 | 87,353,000 | 71,149,000 | 60,563,000 | 62,798,000 | 57,020,000 | 68,930,000 | 41,946,000 | 46,964,000 | 41,889,000 | 45,381,000 | 39,551,000 | 35,991,000 | 35,193,000 | 34,035,000 | 24,617,000 | 26,383,000 | 28,985,000 | 24,181,000 | 21,697,000 | 21,402,000 | 25,504,000 | 21,832,000 | 22,797,000 | 19,345,000 | 23,172,000 | 16,655,000 | 17,373,000 | 13,905,000 | 16,307,000 | 14,946,000 | 16,208,000 | 12,516,000 | 16,324,000 | 13,692,000 | 14,685,000 | 27,010,000 | 14,231,000 | 15,053,000 | 12,588,000 | 14,860,000 | 14,764,000 | 15,776,000 | 13,134,000 | 14,139,000 | 14,613,000 | 14,607,000 | 12,021,000 | 11,157,000 | 11,438,000 | 11,601,000 | 7,673,000 | 10,627,000 | 9,170,000 | 8,428,000 | 7,115,000 |
notes payable, net of current portion | 576,000 | 321,000 | 387,000 | 903,000 | 534,000 | 1,511,000 | 804,000 | 1,289,000 | 2,037,000 | 2,194,000 | 2,583,000 | 1,913,000 | 2,912,000 | 4,258,000 | 4,128,000 | 3,587,000 | 2,265,000 | 821,000 | 571,000 | 596,000 | 509,000 | 685,000 | 4,602,000 | 4,361,000 | 4,292,000 | 4,316,000 | 516,000 | 402,000 | 659,000 | 607,000 | 782,000 | 2,728,000 | 3,952,000 | 4,351,000 | ||||||||||||||||||||||||||||||||||||||||||
revolving facility | 26,500,000 | 24,500,000 | 28,000,000 | 11,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
term loan, net of current portion and deferred financing costs | 124,384,000 | 127,093,000 | 128,851,000 | 130,627,000 | 132,382,000 | 134,188,000 | 135,945,000 | 137,702,000 | 139,459,000 | 141,266,000 | 142,098,000 | 142,918,000 | 143,778,000 | 144,631,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred taxes | 35,695,000 | 34,402,000 | 34,055,000 | 29,465,000 | 24,913,000 | 26,531,000 | 27,337,000 | 24,815,000 | 26,487,000 | 23,102,000 | 21,524,000 | 21,303,000 | 23,838,000 | 19,483,000 | 16,067,000 | 14,385,000 | 6,682,000 | 8,281,000 | 8,212,000 | 7,779,000 | 8,570,000 | 8,930,000 | 7,743,000 | 10,071,000 | 10,336,000 | 12,284,000 | 9,872,000 | 9,012,000 | 8,643,000 | 9,584,000 | 10,151,000 | 10,875,000 | 16,027,000 | 15,443,000 | 15,486,000 | 15,736,000 | 13,727,000 | 12,361,000 | 10,789,000 | |||||||||||||||||||||||||||||||||||||
operating lease liabilities, net of current portion | 106,178,000 | 104,279,000 | 100,688,000 | 101,868,000 | 77,001,000 | 78,329,000 | 75,680,000 | 76,653,000 | 76,884,000 | 78,912,000 | 75,460,000 | 77,934,000 | 76,907,000 | 77,776,000 | 72,162,000 | 74,185,000 | 71,209,000 | 66,887,000 | 62,068,000 | 61,985,000 | 60,137,000 | 61,242,000 | 62,577,000 | 60,258,000 | 58,921,000 | 56,711,000 | 55,834,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 5,414,000 | 4,571,000 | 4,903,000 | 18,275,000 | 8,343,000 | 5,507,000 | 2,988,000 | 2,356,000 | 14,758,000 | 12,779,000 | 13,870,000 | 13,029,000 | 4,026,000 | 4,858,000 | 4,262,000 | 7,345,000 | 6,440,000 | 5,442,000 | 4,549,000 | 4,539,000 | 349,000 | 392,000 | 380,000 | 141,000 | 718,000 | 566,000 | 566,000 | 829,000 | 835,000 | 775,000 | 733,000 | 743,000 | 815,000 | 671,000 | 829,000 | 860,000 | 869,000 | 914,000 | 10,925,000 | 9,480,000 | 8,732,000 | 7,378,000 | 6,053,000 | 5,031,000 | 4,196,000 | 728,000 | 706,000 | 1,617,000 | 2,279,000 | 1,434,000 | 653,000 | 605,000 | 623,000 | 599,000 | 587,000 | 572,000 | 3,531,000 | 4,387,000 | 3,513,000 | 2,564,000 | 3,013,000 | 1,698,000 | 1,672,000 | 2,416,000 | 2,297,000 | 698,000 | 929,000 | 689,000 | 696,000 | 615,000 | 730,000 | 717,000 | 829,000 | 1,258,000 | 1,159,000 | |
total liabilities | 413,827,000 | 414,008,000 | 420,679,000 | 408,421,000 | 358,473,000 | 353,165,000 | 345,290,000 | 345,000,000 | 341,981,000 | 344,069,000 | 384,368,000 | 373,586,000 | 332,949,000 | 336,111,000 | 303,639,000 | 296,983,000 | 201,264,000 | 194,810,000 | 182,225,000 | 184,391,000 | 169,765,000 | 191,602,000 | 260,451,000 | 181,394,000 | 188,065,000 | 192,897,000 | 164,718,000 | 92,348,000 | 112,965,000 | 110,768,000 | 101,052,000 | 110,340,000 | 198,971,000 | 209,419,000 | 194,957,000 | 162,543,000 | 82,829,000 | 90,547,000 | 94,396,000 | 75,721,000 | 73,849,000 | 69,961,000 | 77,174,000 | 75,395,000 | 71,348,000 | 69,014,000 | 32,948,000 | 35,201,000 | 37,197,000 | 37,055,000 | 33,549,000 | 38,066,000 | 38,601,000 | 41,672,000 | 41,974,000 | 32,255,000 | 33,416,000 | 24,478,000 | 20,440,000 | 20,678,000 | 29,435,000 | 19,204,000 | 22,251,000 | 27,104,000 | 31,244,000 | 30,425,000 | 25,798,000 | 29,956,000 | 23,540,000 | 21,197,000 | 26,471,000 | 10,175,000 | 13,239,000 | 12,069,000 | 11,349,000 | 10,020,000 |
redeemable non-controlling interest - temporary equity | 277,661,000 | 263,298,000 | 260,047,000 | 269,025,000 | 186,602,000 | 184,354,000 | 190,733,000 | 174,828,000 | 174,697,000 | 165,514,000 | 164,283,000 | 167,515,000 | 148,155,000 | 151,400,000 | 158,008,000 | 155,262,000 | 138,217,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. physical therapy, inc. (“usph”) shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.01 par value, 500,000 shares authorized, no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 152,000 | 152,000 | 152,000 | 152,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 150,000 | 150,000 | 149,000 | 149,000 | 149,000 | 149,000 | 149,000 | 149,000 | 148,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 146,000 | 145,000 | 145,000 | 145,000 | 145,000 | 144,000 | 143,000 | 143,000 | 143,000 | 142,000 | 141,000 | 141,000 | 140,000 | 140,000 | 139,000 | 141,000 | 141,000 | 140,000 | 139,000 | 139,000 | 138,000 | 138,000 | 138,000 | 138,000 | 137,000 | 139,000 | 142,000 | 142,000 | 141,000 | 141,000 | 141,000 | 140,000 | 138,000 | 138,000 | 137,000 | 136,000 | |
additional paid-in capital | 296,806,000 | 294,636,000 | 292,773,000 | 290,321,000 | 287,002,000 | 285,462,000 | 283,546,000 | 281,096,000 | 279,124,000 | 277,493,000 | 112,123,000 | 110,317,000 | 108,515,000 | 106,801,000 | 105,205,000 | 102,688,000 | 101,922,000 | 99,039,000 | 97,286,000 | 95,622,000 | 93,195,000 | 91,258,000 | 89,756,000 | 87,383,000 | 85,828,000 | 84,125,000 | 82,295,000 | 80,028,000 | 78,542,000 | 77,099,000 | 75,543,000 | 73,940,000 | 72,262,000 | 71,197,000 | 70,132,000 | 68,687,000 | 49,506,000 | 48,236,000 | 46,563,000 | 45,829,000 | 45,080,000 | 43,577,000 | 42,457,000 | 41,306,000 | 40,435,000 | 40,569,000 | 39,225,000 | 38,571,000 | 37,871,000 | 37,489,000 | 37,769,000 | 37,209,000 | 36,563,000 | 36,133,000 | 37,039,000 | 37,513,000 | 39,529,000 | 45,570,000 | 44,114,000 | 43,742,000 | 43,514,000 | 43,210,000 | 39,380,000 | 38,865,000 | 41,418,000 | 43,648,000 | 43,231,000 | 42,383,000 | 41,931,000 | 41,452,000 | 40,979,000 | 37,365,000 | 36,797,000 | 36,304,000 | 35,058,000 | 35,037,000 |
accumulated other comprehensive gain | 945,000 | 1,214,000 | 1,783,000 | 2,799,000 | 1,339,000 | 4,084,000 | 4,108,000 | 2,782,000 | 5,746,000 | 4,796,000 | 2,651,000 | 4,004,000 | 4,424,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
retained earnings | 237,272,000 | 236,356,000 | 234,161,000 | 227,265,000 | 225,873,000 | 226,482,000 | 223,573,000 | 223,772,000 | 238,557,000 | 237,665,000 | 234,760,000 | 232,948,000 | 235,683,000 | 232,247,000 | 227,243,000 | 224,395,000 | 219,338,000 | 216,286,000 | 210,375,000 | 212,015,000 | 203,201,000 | 195,473,000 | 182,785,000 | 184,352,000 | 181,135,000 | 176,610,000 | 168,952,000 | 167,396,000 | 164,821,000 | 165,991,000 | 162,907,000 | 162,406,000 | 157,702,000 | 155,068,000 | 152,642,000 | 150,342,000 | 160,746,000 | 157,161,000 | 152,219,000 | 140,933,000 | 136,491,000 | 134,186,000 | 130,683,000 | 126,934,000 | 121,970,000 | 119,206,000 | 116,555,000 | 117,538,000 | 113,835,000 | 111,321,000 | 113,112,000 | 109,615,000 | 105,825,000 | 102,405,000 | 97,509,000 | 96,632,000 | 92,679,000 | 89,876,000 | 85,729,000 | 83,255,000 | 78,804,000 | 75,632,000 | 78,923,000 | 75,822,000 | 72,200,000 | 69,446,000 | 67,213,000 | 64,682,000 | 61,827,000 | 59,442,000 | 56,956,000 | 54,836,000 | 52,533,000 | 50,704,000 | 45,892,000 | 44,408,000 |
treasury stock | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -26,106,000 | |
total usph shareholders’ equity | 503,567,000 | 500,750,000 | 497,261,000 | 488,929,000 | 482,758,000 | 484,572,000 | 479,771,000 | 476,194,000 | 491,971,000 | 488,498,000 | 318,058,000 | 315,793,000 | 317,146,000 | 307,177,000 | 300,971,000 | 295,606,000 | 289,783,000 | 283,848,000 | 276,184,000 | 276,160,000 | 264,919,000 | 255,254,000 | 241,064,000 | 240,257,000 | 235,485,000 | 229,256,000 | 219,768,000 | 215,945,000 | 211,884,000 | 211,611,000 | 206,971,000 | 204,866,000 | 198,483,000 | 194,784,000 | 191,293,000 | 187,548,000 | ||||||||||||||||||||||||||||||||||||||||
non-controlling interest - permanent equity | 1,215,000 | 1,544,000 | 1,700,000 | 1,092,000 | 1,358,000 | 1,043,000 | 1,462,000 | 1,216,000 | 1,537,000 | 1,500,000 | 1,418,000 | 1,260,000 | 1,458,000 | 1,756,000 | 1,245,000 | 1,575,000 | 834,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders’ equity and non-controlling interest - permanent equity | 504,782,000 | 502,294,000 | 498,961,000 | 490,021,000 | 484,116,000 | 485,615,000 | 481,233,000 | 477,410,000 | 493,508,000 | 489,998,000 | 319,476,000 | 317,053,000 | 318,604,000 | 308,933,000 | 302,216,000 | 290,617,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interest, usph shareholders’ equity and non-controlling interest - permanent equity | 1,196,270,000 | 1,179,600,000 | 1,179,687,000 | 1,167,467,000 | 1,029,191,000 | 1,023,134,000 | 1,017,256,000 | 997,238,000 | 1,010,186,000 | 999,581,000 | 868,127,000 | 858,154,000 | 799,708,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 3,928 and 3,506, respectively | 65,956,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 3,620 and 3,506, respectively | 64,760,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 3,506 and 2,736, respectively | 59,040,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 3,443 and 2,736, respectively | 57,022,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 3,184 and 2,736, respectively | 54,659,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 2,936 and 2,736, respectively | 55,363,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less benefit from credit losses of 2,736 and 2,829, respectively | 51,866,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable - due to seller of acquired business | 3,204,000 | 3,203,000 | 3,203,000 | 3,203,000 | 3,203,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,487 and 2,829, respectively | 52,958,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,800 and 2,829, respectively | 54,285,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revolving line of credit | 38,000,000 | 31,000,000 | 118,000,000 | 114,000,000 | 33,000,000 | 38,000,000 | 16,000,000 | 16,000,000 | 7,000,000 | 33,000,000 | 114,000,000 | 46,000,000 | 51,000,000 | 62,000,000 | 29,000,000 | 38,000,000 | 54,000,000 | 56,000,000 | 42,000,000 | 54,000,000 | 56,000,000 | 69,000,000 | 58,000,000 | 46,000,000 | 36,000,000 | 42,500,000 | 52,500,000 | 41,000,000 | 41,500,000 | 34,500,000 | 46,500,000 | 45,000,000 | 45,500,000 | 40,000,000 | 14,150,000 | 15,750,000 | 20,400,000 | 17,400,000 | 16,100,000 | 20,000,000 | 24,200,000 | 23,500,000 | 26,400,000 | 15,800,000 | 4,800,000 | 5,500,000 | 3,600,000 | 10,900,000 | 400,000 | 3,400,000 | 10,600,000 | 12,600,000 | 11,400,000 | 8,800,000 | 14,800,000 | 9,800,000 | 7,000,000 | 12,000,000 | ||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,674 and 2,829, respectively | 56,647,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,829 and 2,768, respectively | 51,934,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,964 and 2,768, respectively | 49,747,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,948 and 2,768, respectively | 50,549,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss | -395,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interest, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
usph shareholders’ equity and non-controlling interest - permanent equity | 796,444,000 | 763,863,000 | 630,098,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,799 and 2,768, respectively | 49,335,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of notes payable | 799,000 | 830,000 | 672,000 | 1,017,000 | 5,079,000 | 4,899,000 | 4,999,000 | 4,635,000 | 728,000 | 728,000 | 718,000 | 690,000 | 1,066,000 | 1,434,000 | 4,769,000 | 4,817,000 | 5,317,000 | 4,044,000 | 2,745,000 | 2,345,000 | 1,219,000 | 1,227,000 | 986,000 | 1,044,000 | 1,253,000 | 800,000 | 932,000 | 883,000 | 850,000 | 850,000 | 775,000 | 825,000 | 575,000 | 800,000 | 659,000 | 459,000 | 609,000 | 609,000 | 483,000 | 433,000 | 533,000 | 434,000 | 250,000 | 250,000 | 379,000 | 637,000 | 1,113,000 | 1,013,000 | 1,086,000 | 1,234,000 | 1,307,000 | 1,380,000 | 1,153,000 | 1,179,000 | 771,000 | 812,000 | 854,000 | 537,000 | 537,000 | 562,000 | ||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,768 and 2,008, respectively | 46,272,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders' equity and non-controlling interest - permanent equity | 297,181,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interest, usph shareholders' equity and non-controlling interest - permanent equity | 749,426,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,728 and 2,008, respectively | 46,456,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,435 and 2,008, respectively | 45,144,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interests, usph shareholders’ equityand non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interests - temporary equity | 143,337,000 | 138,924,000 | 132,340,000 | 139,801,000 | 136,728,000 | 140,498,000 | 137,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests - permanent equity | 963,000 | 1,057,000 | 1,470,000 | 953,000 | 1,444,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders’ equity and non-controlling interests - permanent equity | 284,811,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
usph shareholders’ equity and non-controlling interests - permanent equity | 622,958,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,120 and 2,008, respectively | 45,394,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interests, usph shareholders’ equity and non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable - purchase of non-controlling interest | 4,828,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders' equity and non-controlling interests - permanent equity | 277,241,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, usph shareholders' equity and non-controlling interests - permanent equity | 598,390,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,008 and 2,698, respectively | 41,906,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interests, usphshareholders’ equity and non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders' equity and non-controlling interests | 277,630,000 | 241,701,000 | 221,173,000 | 213,098,000 | 212,748,000 | 208,485,000 | 199,937,000 | 195,966,000 | 192,714,000 | 188,688,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, usph shareholders' equity and non-controlling interests | 594,361,000 | 560,845,000 | 523,087,000 | 454,969,000 | 440,543,000 | 417,622,000 | 410,987,000 | 417,325,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,154 and 2,698, respectively | 39,439,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders’ equity and non-controlling interests | 265,872,000 | 256,688,000 | 242,304,000 | 237,327,000 | 230,747,000 | 216,875,000 | 206,070,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, usph shareholders’ equity and non-controlling interests | 575,438,000 | 585,018,000 | 643,253,000 | 565,193,000 | 557,010,000 | 443,166,000 | 418,982,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,470 and 2,698, respectively | 36,029,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests- permanent equity | 1,434,000 | 1,240,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,557 and 2,698, respectively | 42,649,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,698 and 2,672, respectively | 46,228,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred rent | 2,159,000 | 1,864,000 | 1,913,000 | 2,005,000 | 2,116,000 | 1,875,000 | 1,789,000 | 1,809,000 | 1,575,000 | 1,313,000 | 1,285,000 | 1,391,000 | 1,040,000 | 984,000 | 991,000 | 1,014,000 | 1,095,000 | 1,022,000 | 996,000 | 1,015,000 | 972,000 | 950,000 | 894,000 | 894,000 | 930,000 | 946,000 | 941,000 | 849,000 | 849,000 | 884,000 | 966,000 | 900,000 | 877,000 | 1,011,000 | 1,027,000 | 1,097,000 | 1,161,000 | 1,077,000 | 1,103,000 | 887,000 | 992,000 | 1,008,000 | 1,104,000 | 1,171,000 | 1,256,000 | 1,239,000 | 1,273,000 | 1,248,000 | 1,263,000 | |||||||||||||||||||||||||||
preferred stock, .01 par value, 500,000 shares authorized, no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,569 and 2,672, respectively | 47,118,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interests | 139,801,000 | 133,366,000 | 137,196,000 | 133,943,000 | 128,906,000 | 117,027,000 | 108,085,000 | 102,572,000 | 12,079,000 | 11,940,000 | 8,334,000 | 8,641,000 | 7,591,000 | 10,585,000 | 7,373,000 | 7,376,000 | 7,524,000 | 1,086,000 | 2,967,000 | 4,104,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests | 1,842,000 | 1,491,000 | 1,405,000 | 930,000 | 1,214,000 | 1,137,000 | 1,514,000 | 1,204,000 | 1,454,000 | 1,182,000 | 1,421,000 | 1,140,000 | 39,967,000 | 40,494,000 | 42,146,000 | 26,734,000 | 26,113,000 | 20,934,000 | 21,382,000 | 27,542,000 | 23,398,000 | 22,414,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,666 and 2,672, respectively | 44,923,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable, net - sale and purchase of partnership interests | 9,401,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,692 and 2,672, respectively | 48,443,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. physical therapy, inc. ("usph") shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,672 and 2,273, respectively | 44,751,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
mandatorily redeemable non-controlling interests | 327,000 | 84,311,000 | 83,643,000 | 80,154,000 | 69,190,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,690 and 2,273, respectively | 43,899,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,790 and 2,273, respectively | 45,424,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,517 and 2,273, respectively | 46,228,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,273 and 1,792, respectively | 44,707,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,088 and 1,792, respectively | 43,561,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,859 and 1,792, respectively | 46,770,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,853 and 1,792, respectively | 43,244,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, usph shareholders’ equity and non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable | 4,802,000 | 4,596,000 | 4,546,000 | 4,547,000 | 4,621,000 | 1,059,000 | 483,000 | 234,000 | 450,000 | 450,000 | 450,000 | 650,000 | 400,000 | 400,000 | 325,000 | 175,000 | 175,000 | 275,000 | 334,000 | 284,000 | 434,000 | 334,000 | 150,000 | 250,000 | 100,000 | 100,000 | 100,000 | 280,000 | 537,000 | 1,012,000 | 1,012,000 | 806,000 | 1,214,000 | 886,000 | 959,000 | 1,084,000 | 516,000 | 656,000 | 797,000 | 244,000 | 244,000 | |||||||||||||||||||||||||||||||||||
total liabilities, usph shareholders' equity and non-controlling interests | 387,671,000 | 351,231,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,792 and 1,444, respectively | 38,840,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of -0- and 198, respectively | 2,649,000 | 2,272,000 | 2,335,000 | 2,345,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,770 and 1,444, respectively | 38,522,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. physical therapy, inc. shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total u. s. physical therapy, inc. shareholders’ equity | 178,771,000 | 173,916,000 | 167,301,000 | 146,280,000 | 128,290,000 | 124,295,000 | 124,624,000 | 120,220,000 | 117,323,000 | 119,394,000 | 115,336,000 | 110,900,000 | 107,049,000 | 103,061,000 | 102,658,000 | 100,720,000 | 103,957,000 | 98,354,000 | 95,507,000 | 90,828,000 | 87,352,000 | 86,813,000 | 83,196,000 | 82,129,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
total equity | 218,738,000 | 214,410,000 | 209,447,000 | 182,014,000 | 176,201,000 | 167,214,000 | 163,039,000 | 164,299,000 | 154,319,000 | 151,017,000 | 146,709,000 | 147,229,000 | 139,680,000 | 134,659,000 | 136,391,000 | 132,566,000 | 125,835,000 | 121,580,000 | 122,065,000 | 114,582,000 | 112,958,000 | 116,383,000 | 106,514,000 | 103,788,000 | 99,189,000 | 92,225,000 | 91,861,000 | 88,561,000 | 87,789,000 | |||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and equity | 309,901,000 | 313,598,000 | 311,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,672 and 1,444, respectively | 39,356,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,568 and 1,444, respectively | 38,217,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u. s. physical therapy, inc. shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,618 and 1,669, respectively | 34,830,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 198 and 198, respectively | 1,338,000 | 1,378,000 | 1,503,000 | 1,906,000 | 1,924,000 | 1,698,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangible assets | 24,167,000 | 24,537,000 | 24,907,000 | 22,615,000 | 15,727,000 | 15,916,000 | 14,479,000 | 14,672,000 | 14,029,000 | 14,230,000 | 12,146,000 | 12,326,000 | 12,522,000 | 9,515,000 | 9,603,000 | 9,773,000 | 9,948,000 | 7,166,000 | 7,308,000 | 7,448,000 | 7,569,000 | 5,830,000 | 5,955,000 | 6,079,000 | 6,203,000 | 6,327,000 | 6,452,000 | 5,370,000 | 3,926,000 | 3,981,000 | 3,930,000 | |||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders' equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u. s. physical therapy, inc. shareholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total u. s. physical therapy, inc. shareholders' equity | 155,280,000 | 150,088,000 | 141,657,000 | 136,757,000 | 130,921,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,633 and 1,669, respectively | 34,673,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,669 and 1,430, respectively | 32,891,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders' equity | 244,551,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,811 and 1,430, respectively | 33,809,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,713 and 1,430, respectively | 34,286,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,583 and 1,430, respectively | 32,755,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,430 and 1,595, respectively | 30,820,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 198 and 514, respectively | 1,844,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncontrolling interests | 22,727,000 | 22,605,000 | 19,460,000 | 17,336,000 | 16,997,000 | 17,230,000 | 14,935,000 | 14,531,000 | 19,004,000 | 11,924,000 | 12,238,000 | 12,426,000 | 8,160,000 | 8,281,000 | 8,361,000 | 4,873,000 | 5,048,000 | 5,365,000 | 5,660,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,427 and 1,595, respectively | 27,289,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable—other, less allowance for doubtful accounts of 198 and 514, respectively | 1,263,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable—trade | 1,301,000 | 1,732,000 | 1,377,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,469 and 1,595, respectively | 27,564,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 412 and 514, respectively | 1,700,000 | 1,607,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,521 and 1,595, respectively | 28,969,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,595 and 2,154, respectively | 25,973,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable—other, less allowance for doubtful accounts of 514 and 883, respectively | 1,703,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash | 10,683,000 | 8,811,000 | 10,440,000 | 9,475,000 | 8,992,000 | 10,666,000 | 9,720,000 | 7,176,000 | 11,471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,687 and 2,154, respectively | 26,784,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 373 and 883, respectively | 1,640,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable — trade | 1,665,000 | 1,809,000 | 1,810,000 | 1,517,000 | 1,477,000 | 1,237,000 | 1,224,000 | 1,522,000 | 1,188,000 | 1,292,000 | 1,211,000 | 1,090,000 | 1,280,000 | 1,481,000 | 1,275,000 | 1,514,000 | 1,321,000 | 1,555,000 | 1,212,000 | 696,000 | 1,059,000 | 1,601,000 | 1,721,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,930 and 2,154, respectively | 28,768,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 408 and 883, respectively | 1,737,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,892 and 2,154, respectively | 29,456,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable—other, less allowance for doubtful accounts of 186 and 883, respectively | 1,979,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,154 and 2,190, respectively | 28,333,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 883 and 83, respectively | 1,614,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,155 and 2,190, respectively | 28,130,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful. accounts of 916 and 83, respectively | 1,999,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,570 and 2,190, respectively | 27,468,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 136 and 83, respectively | 2,613,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,500 and 2,190, respectively | 27,987,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 106 and 83, respectively | 1,941,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,190 and 1,830, respectively | 24,814,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 83 and 42, respectively | 1,555,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,226 and 1,830, respectively | 23,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 81 and 42, respectively | 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,215 and 1,830, respectively | 23,115,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 59 and 42, respectively | 1,565,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,031 and 1,830, respectively | 23,482,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 50 and 42, respectively | 2,146,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,830 and 2,275, respectively | 22,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 42 and — , respectively | 1,331,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u. s. physical therapy, inc. shareholders’s equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,976 and 2,275, respectively | 23,715,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other | 706,000 | 707,000 | 701,000 | 898,000 | 920,000 | 1,020,000 | 1,150,000 | 1,075,000 | 793,000 | 602,000 | 775,000 | 761,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,062 and 2,275, respectively | 23,696,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,177 and 2,275, respectively | 25,650,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,275 and 2,184, respectively | 25,853,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interests in subsidiary limited partnerships | 6,214,000 | 6,135,000 | 6,347,000 | 5,847,000 | 5,648,000 | 5,484,000 | 3,994,000 | 3,723,000 | 3,871,000 | 3,344,000 | 3,024,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 81,608,000 | 78,958,000 | 75,578,000 | 72,271,000 | 69,407,000 | 66,447,000 | 60,711,000 | 57,840,000 | 55,517,000 | 53,475,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,128 and 2,184, respectively | 26,935,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable – other | 872,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,181 and 2,184, respectively | 28,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,142 and 2,184, respectively | 27,581,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
marketable securities — available for sale | 1,900,000 | 1,460,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,184 and 1,567, respectively | 25,574,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,950 and 1,567, respectively | 25,976,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,745 and 1,567, respectively | 22,328,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,669 and 1,567, respectively | 21,873,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,567 and 1,621, respectively | 21,503,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts of 1,656 and 1,621, respectively | 20,372,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable -- other | 839,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable -- trade | 1,410,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable - long-term portion | 415,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, .01 par value, 500,000 shares authorized, no | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
13,647,047 and 13,645,167 shares issued at march 31, 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and december 31, 2005, respectively | 136,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital, equity-based compensation | 222,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
march 31, 2006 and december 31, 2005, respectively | -26,966,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders' equity | 54,342,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,621 and 2,447, respectively | 19,661,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable — long-term portion | 483,000 |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.